Strides Pharma Signs US Nasal Drug Products Deal with Kenox

Strides Pharma Science announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Singapore, has signed an agreement with Kenox Pharmaceuticals, a high-growth contract development and manufacturing organization with a focus on Orally Inhaled and Nasal Drug Products (OINDPs), to enter into a strategic product development partnership.  

Strides will work closely with Kenox to develop and file multiple nasal spray products in the US, for various therapeutic indications. The exact number of products and details of the product remain confidential, but the collaboration is aimed at accelerating access to affordable, high-quality therapeutic choices in a growing part of the US pharmaceutical market.

Also Read: Balancing Innovation and Affordability in Medical Solutions for India

“We are delighted to announce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space… accelerate our range of nasal spray offerings in the US market.” said Aditya Kumar, Executive Director Business Development, Strides Pharma Science.

Dr. Sitaram Velaga, Founder, President and CEO of Kenox Pharmaceuticals, added: “Our strategic partnership with Strides is a significant milestone for Kenox. This collaboration validates our expertise in the OINDP space and will allow us to leverage our capabilities to bring important drug products to global patients at an affordable price.”

The partnership brings together Strides’ strong commercial presence in the United States and Kenox’s proven expertise in OINDPs, positioning both companies to address growing demand for nasal spray products across critical treatment areas. Industry watchers view this move as a strategic step for Strides to expand its specialty portfolio while strengthening its competitive edge in one of the world’s largest healthcare markets.